Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Multi-center, Double-blind, Randomized, Placebo-controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2

NCT00811889 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00811889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Multi-center, Double-blind, Randomized, Placebo-controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
December 31, 2010
Enrollment
227 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, diabetic nephropathy, type 2 diabetes